Table 3. Efficacy of crizotinib in patients with 21 cases of ALK positive NSCLC positive patients with TP53 gene status.
| TP53 gene status | CR | PR | SD | PD | ORR/% | DCR/% | PFS (months) |
|---|---|---|---|---|---|---|---|
| TP53 wild | 0 | 10 | 1 | 2 | 76.92 | 84.62 | 10.4 |
| TP53 mutation | 0 | 3 | 1 | 4 | 37.50 | 50.00 | 3.3 |
ALK, anaplastic lymphoma kinase; NSCLC, non-small lung cancer cell; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival.